IRIS

Sfoglia per Autore  

Opzioni
Mostrati risultati da 21 a 40 di 130
Titolo Data di pubblicazione Autore(i) File
Outcome and Safety of Sorafenib in Metastatic Renal Cell Carcinoma Dialysis Patients: A Systematic Review 1-gen-2016 Leonetti, A.; Bersanelli, M.; Castagneto, B.; Masini, C.; Di Meglio, G.; Pellegrino, B.; Buti, S.
Inside the 2016 American Society of Clinical Oncology Genitourinary Cancers Symposium: Part 2 - Prostate and bladder cancer 1-gen-2016 Buti, S.; Ciccarese, C.; Iacovelli, R.; Bersanelli, M.; Scarpelli, M.; Lopez-Beltran, A.; Cheng, L.; Montironi, R.; Tortora, G.; Massari, F.
Primary Retroperitoneal Cystoadenocarcinoma: A Systematic Review 1-gen-2016 Pellegrino, B.; Sikokis, A.; Bersanelli, M.; Leonetti, A.; Leonardi, F.; Di Meglio, G.; Buti, S.
From targeting the tumor to targeting the immune system: Transversal challenges in oncology with the inhibition of the PD-1/PD-L1 axis 1-gen-2017 Bersanelli, M.; Buti, S.
Plasma genotyping for EGFR T790M in non-small cell lung cancer: Ready for clinical practice? 1-gen-2017 Bersanelli, M.; Gelsomino, F.; Buti, S.; Fiorentino, M.; Tiseo, M.
Validation of a new prognostic model to easily predict outcome in renal cell carcinoma: The GRANT score applied to the ASSURE trial population 1-gen-2017 Buti, S.; Puligandla, M.; Bersanelli, M.; Dipaola, R. S.; Manola, J.; Taguchi, S.; Haas, N. B.
Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study 1-gen-2017 Buti, S.; Donini, M.; Bersanelli, M.; Gattara, A.; Leonardi, F.; Passalacqua, R.
Clinical use of lenvatinib in combination with everolimus for the treatment of advanced renal cell carcinoma 1-gen-2017 Leonetti, A.; Leonardi, F.; Bersanelli, M.; Buti, S.
Circulating immune-profile as predictor of outcome in advanced NSCLC patients treated with Nivolumab 1-gen-2017 Tiseo, M.; Facchinetti, F.; Buti, S.; Gelsomino, F.; Veneziani, M.; Squadrilli, A.; Bordi, P.; Bersanelli, M.; Cosenza, A.; Ferri, L.; Rapacchi, E.; Mazzaschi, G.; Leonardi, F.; Quaini, F.; Ardizzoni, A.; Missale, G.
“Finding NEMO” in NRAS-mutant melanoma: a step towards a sequential strategy? 1-gen-2017 Bersanelli, M.; Leonetti, A.; Buti, S.; Michiara, M.
The link between calcitriol and anticancer immunotherapy: Vitamin D as the possible balance between inflammation and autoimmunity in the immune-checkpoint blockade 1-gen-2017 Bersanelli, M.; Leonetti, A.; Buti, S.
Benefit of adjuvant immunotherapy in renal cell carcinoma: A myth or a reality? 1-gen-2017 Taguchi, S.; Buti, S.; Fukuhara, H.; Otsuka, M.; Bersanelli, M.; Morikawa, T.; Miyazaki, H.; Nakagawa, T.; Fujimura, T.; Kume, H.; Igawa, Y.; Homma, Y.
Is cabozantinib really better than sunitinib as first-line treatment of metastatic renal cell carcinoma? 1-gen-2017 Buti, S.; Bersanelli, M.
First-Line PAzopanib in NOn–clear-cell Renal cArcinoMA: The Italian Retrospective Multicenter PANORAMA Study 1-gen-2017 Buti, S.; Bersanelli, M.; Maines, F.; Facchini, G.; Gelsomino, F.; Zustovich, F.; Santoni, M.; Verri, E.; De Giorgi, U.; Masini, C.; Morelli, F.; Vitale, M. G.; Sava, T.; Prati, G.; Librici, C.; Fraccon, A. P.; Fornarini, G.; Maruzzo, M.; Leonardi, F.; Caffo, O.
Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer 1-gen-2017 Iacovelli, R.; Cossu Rocca, M.; Galli, L.; De Giorgi, U.; Sabbatini, R.; Santoni, M.; Mosca, A.; Fornarini, G.; Massari, F.; Masini, C.; Bersanelli, M.; Biasco, E.; Lolli, C.; Guida, A.; Berardi, R.; Terrone, C.; Pastorino, A.; Ardizzoni, A.; Pinto, C.; Buti, S.; Nole, F.; Tortora, G.
Cabozantinib in metastatic renal cell carcinoma: Latest findings and clinical potential 1-gen-2017 Bersanelli, M.; Buti, S.
PREDICTIVE AND PROGNOSTIC VALUE OF CLINICAL AND MOLECULAR FEATURES IN PATIENTS UNDERGOING PULMONARY METASTASECTOMY FROM RENAL CELL CARCINOMA 1-gen-2018 Ampollini, Luca; Bersanelli, M.; Gnetti, L.; Varotti, E.; Ziglioli, F.; Indira Dadomo, C.; Ventura, L.; Braggio, C.; Bocchialini, G.; Campanini, N.; Rapacchi, E.; Caruso, Giuseppe; Silini, E. M.; Maestroni, U.; Carbognani, P.; Rusca, M.; Leonardi, F.; Buti, S.
Correction to: Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study (Drugs in R&D, (2017), 17, 4, (585-596), 10.1007/s40268-017-0209-5) 1-gen-2018 Buti, S.; Donini, M.; Bersanelli, M.; Gattara, A.; Leonardi, F.; Passalacqua, R.
Spotlight on cabozantinib for previously untreated advanced renal cell carcinoma: Evidence to date 1-gen-2018 Bersanelli, M.; Leonardi, F.; Buti, S.
Patient performance status and cancer immunotherapy efficacy: a meta-analysis 1-gen-2018 Bersanelli, M.; Brighenti, M.; Buti, S.; Barni, S.; Petrelli, F.
Mostrati risultati da 21 a 40 di 130
Legenda icone

  •  file ad accesso aperto
  •  file disponibili sulla rete interna
  •  file disponibili agli utenti autorizzati
  •  file disponibili solo agli amministratori
  •  file sotto embargo
  •  nessun file disponibile